Linear Health Sciences

Executive Summary

Linear Health Sciences addresses the widespread clinical challenge of intravenous (IV) line dislodgements, which cause patient discomfort, treatment delays, and increased healthcare costs. Their lead product, Orchid SRV (Secure Release Valve), is designed to prevent accidental IV dislodgements by allowing the catheter to separate cleanly from the tubing under tension, reducing the risk of painful dislodgement and the need for reinsertion. Particularly impactful in pediatric populations—who face the highest rates of vascular access failure—the Orchid SRV offers a simple, cost-effective solution that improves patient outcomes and reduces workflow burden for clinicians. The company is privately held, based in Oklahoma City, and has been developing its technology since 2015. While specific financial and regulatory milestones are not yet public, the product has received attention from the medical device community for its potential to address a persistent gap in IV therapy safety.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Orchid SRV75% success
• Q2 2027First Major Hospital System Partnership50% success
• Q4 2026Publication of Pediatric Clinical Study Results60% success